DaxibotulinumtoxinA (Daxxify) for Frown Lines (online only)
DaxibotulinumtoxinA (Daxxify) for Frown Lines (online only)
July 22, 2024 (Issue: 1707)
The FDA has approved daxibotulinumtoxinA-lanm
(Daxxify – Revance), an acetylcholine release inhibitor
and neuromuscular blocking agent, for temporary
improvement in the appearance of moderate to severe
glabellar (frown) lines associated with...more
- R Small. Botulinum toxin injection for facial wrinkles. Am Fam Physician 2014; 90:168.
- N Solish et al. Overview of daxibotulinumtoxinA for injection: a novel formulation of botulinum toxin type A. Drugs 2021; 81:2091. doi:10.1007/s40265-021-01631-w
- JD Carruthers et al. DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg 2020; 145:45. doi:10.1097/prs.000000000000632
- SG Fabi et al. DaxibotulinumtoxinA for injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. Dermatol Surg 2021; 47:48. doi:10.1097/dss.0000000000002531
- S Ahsanuddin et al. Adverse events associated with Botox as reported in a Food and Drug Administration database. Aesthetic Plast Surg 2021; 45:1201. doi:10.1007/s00266-020-02027-z
- S-K Lee and HJ Jun. Esotropia following botulinum toxin type A injection for facial wrinkles. J Cosmet Laser Ther 2018; 20:50. doi:10.1080/14764172.2017.1349322
- M Alam et al. Severe, intractable headache after injection with botulinum A exotoxin: report of 5 cases. J Am Acad Dermatol 2002; 46:62. doi:10.1067/mjd.2001.118342
- MK Trivedi et al. A review of the safety of cosmetic procedures during pregnancy and lactation. Int J Womens Dermatol 2017; 3:6. doi:10.1016/j.ijwd.2017.01.005
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: DaxibotulinumtoxinA (Daxxify) for Frown Lines (online only)
Article code: 1707g
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
